References
- Gardner-Medwin D. Clinical features and classification of the muscular dystrophies. Br Med Bull. 1980;36(2):109–16. doi:https://doi.org/10.1093/oxfordjournals.bmb.a071623.
- Kieny P, Chollet S, Delalande P, Le Fort M, Magot A, Pereon Y, Perrouin Verbe B. Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre between 1981 and 2011. Ann Phys Rehabil Med. 2013;56(6):443–54. doi:https://doi.org/10.1016/j.rehab.2013.06.002.
- Moat SJ, Bradley DM, Salmon R, Clarke A, Hartley L. Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK). Eur J Hum Genet. 2013;21(10):1049–53. doi:https://doi.org/10.1038/ejhg.2012.301.
- Mercuri E, Muntoni F. Muscular dystrophies. Lancet. 2013;381(9869):845–60. doi:https://doi.org/10.1016/S0140-6736(12)61897-2.
- Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord. 2002;12(10):926–29. doi:https://doi.org/10.1016/S0960-8966(02)00140-2.
- Eagle M, Bourke J, Bullock R, Gibson M, Mehta J, Giddings D, Straub V, Bushby K. Managing Duchenne muscular dystrophy–the additive effect of spinal surgery and home nocturnal ventilation in improving survival. Neuromuscul Disord. 2007;17(6):470–75. doi:https://doi.org/10.1016/j.nmd.2007.03.002.
- Bach JR, Martinez D. Duchenne muscular dystrophy: continuous noninvasive ventilatory support prolongs survival. Respir Care. 2011;56(6):744–50. doi:https://doi.org/10.4187/respcare.00831.
- Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, Case LE, Clemens PR, Hadjiyannakis S, Pandya S, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17(3):251–67. doi:https://doi.org/10.1016/S1474-4422(18)30024-3.
- Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A, Case LE, Cripe L, Hadjiyannakis S, Olson AK, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol. 2018;17(4):347–61. doi:https://doi.org/10.1016/S1474-4422(18)30025-5.
- Bérard C, Payan C, Hodgkinson I, Fermanian J, MFM Collaborative Study Group T. A motor function measure scale for neuromuscular diseases. Construction and validation study. Neuromuscul Disord. 2005;15(7):463–70. doi:https://doi.org/10.1016/j.nmd.2005.03.004.
- De Lattre C, Payan C, Vuillerot C, Rippert P, de Castro D, Bérard C, Poirot I. Motor function measure: validation of a short form for young children with neuromuscular diseases. Arch Phys Med Rehabil. 2013;94(11):2218–26. doi:https://doi.org/10.1016/j.apmr.2013.04.001.
- EMA. Guideline on the clinical investigation of medicinal products for the treatment of Duchenne and Becker muscular dystrophy. 2015. doi:EMA/CHMP/236981/2011,Corr.11.
- MFM. MFM user’s manual. 2019 [accessed 2020]. https://mfm-nmd.org/get-a-user-manual/?lang=en.
- Huang M, Cao J, Sun J, Li W, Qin L, Li H, Zhai C, Huang W, Gui T, Zhang K, et al. Cross-cultural adaptation and multi-centric validation of the motor function measure Chinese version (MFM-32-CN) for patients with neuromuscular diseases. Dev Neurorehabil. 2020 May;23(4):210–17. doi:https://doi.org/10.1080/17518423.2019.1642413.
- Beaton DE. Understanding the relevance of measured change through studies of responsiveness. Spine. 2000;25(24):3192–99. doi:https://doi.org/10.1097/00007632-200012150-00015.
- Husted JA, Cook RJ, Farewell VT, Gladman DD. Methods for assessing responsiveness: a critical review and recommendations. J Clin Epidemiol. 2000;53(5):459–68. doi:https://doi.org/10.1016/S0895-4356(99)00206-1.
- Kovacs FM, Abraira V, Royuela A, Corcoll J, Alegre L, Tomás M, Mir MA, Cano A, Muriel A, Zamora J, et al. Minimum detectable and minimal clinically important changes for pain in patients with nonspecific neck pain. BMC Musculoskelet Disord. 2008;9(1):43–43. doi:https://doi.org/10.1186/1471-2474-9-43.
- Beaton DE, Boers M, Wells GA. Many faces of the minimal clinically important difference (MCID): a literature review and directions for future research. Curr Opin Rheumatol. 2002 Mar;14(2):109–14. doi:https://doi.org/10.1097/00002281-200203000-00006.
- Vuillerot C, Payan C, Girardot F, Fermanian J, Iwaz J, Bérard C, Ecochard R. Responsiveness of the motor function measure in neuromuscular diseases. Arch Phys Med Rehabil. 2012;93(12):2251–2256. e1. doi:https://doi.org/10.1016/j.apmr.2012.05.025.
- Schreiber A, Brochard S, Rippert P, Fontaine-Carbonnel S, Payan C, Poirot I, Hamroun D, Vuillerot C. Corticosteroids in Duchenne muscular dystrophy: impact on the motor function measure sensitivity to change and implications for clinical trials. Dev Med Child Neurol. 2018;60(2):185–91. doi:https://doi.org/10.1111/dmcn.13590.
- Nagy S, Schädelin S, Hafner P, Bonati U, Scherrer D, Ebi S, Schmidt S, Orsini A-L, Bieri O, Fischer D, et al. Longitudinal reliability of outcome measures in patients with Duchenne muscular dystrophy. Muscle Nerve. 2020;61(1):63–68. doi:https://doi.org/10.1002/mus.26690.
- Hogrel J-Y, Wary C, Moraux A, Azzabou N, Decostre V, Ollivier G, Canal A, Lilien C, Ledoux I, Annoussamy M, et al. Longitudinal functional and NMR assessment of upper limbs in Duchenne muscular dystrophy. Neurology. 2016;86(11):1022–30. doi:https://doi.org/10.1212/WNL.0000000000002464.
- Lilien C, Reyngoudt H, Seferian AM, Gidaro T, Annoussamy M, Chê V, Decostre V, Ledoux I, Le Louër J, Guemas E, et al. Upper limb disease evolution in exon 53 skipping eligible patients with Duchenne muscular dystrophy. Ann Clin Transl Neurol. 2021;8(10):1938–50. doi:https://doi.org/10.1002/acn3.51417.
- Seferian AM, Moraux A, Annoussamy M, Canal A, Decostre V, Diebate O, Le Moing A-G, Gidaro T, Deconinck N, Van Parys F, et al. Upper limb strength and function changes during a one-year follow-up in non-ambulant patients with Duchenne muscular dystrophy: an observational multicenter trial. PLOS ONE. 2015;10(2):e0113999. doi:https://doi.org/10.1371/journal.pone.0113999.
- Trundell D, Le Scouiller S, Gorni K, Seabrook T, Vuillerot C. Validity and reliability of the 32-item motor function measure in 2- to 5-year-olds with neuromuscular disorders and 2- to 25-year-olds with spinal muscular atrophy. Neurol Ther. 2020 Dec;9(2):575–84. doi:https://doi.org/10.1007/s40120-020-00206-3.
- Vignos PJ, Spencer GE, Archibald KC. Management of progressive muscular dystrophy of childhood. Jama. 1963;184(2):89–96. doi:https://doi.org/10.1001/jama.1963.03700150043007.
- Brooke MH, Griggs RC, Mendell JR, Fenichel GM, Shumate JB, Pellegrino RJ. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981;4(3):186–97. doi:https://doi.org/10.1002/mus.880040304.
- Florence JM, Pandya S, King WM, Robison JD, Signore LC, Wentzell M, Province MA. Clinical trials in Duchenne dystrophy: standardization and reliability of evaluation procedures. Phys Ther. 1984;64(1):41–45. doi:https://doi.org/10.1093/ptj/64.1.41.
- Perrot S, Lantéri‐Minet M. Patients’ global impression of change in the management of peripheral neuropathic pain: clinical relevance and correlations in daily practice. Eur J Pain. 2019;23(6):1117–28. doi:https://doi.org/10.1002/ejp.1378.
- Geisser ME, Clauw DJ, Strand V, Gendreau MR, Palmer R, Williams DA. Contributions of change in clinical status parameters to Patient Global Impression of Change (PGIC) scores among persons with fibromyalgia treated with milnacipran. PAIN®. 2010;149(2):373–78. doi:https://doi.org/10.1016/j.pain.2010.02.043.
- Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole MR. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94(2):149–58. doi:https://doi.org/10.1016/S0304-3959(01)00349-9.
- Salaffi F, Stancati A, Silvestri CA, Ciapetti, A, Grassi, W . Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale. Eur J Pain. 2004;8(4):283–91.
- KeithMuller. Statistical power analysis for the behavioral sciences. Technometrics. 1988;31(4):499–500.
- Taylor R. Interpretation of the correlation coefficient: a basic review. J Diagn Med Sonogr. 1990;6(1):35–39. doi:https://doi.org/10.1177/875647939000600106.
- Terwee CB, Bot SD, de Boer MR, van der Windt DAWM, Knol DL, Dekker J, Bouter LM, de Vet HCW. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol. 2007;60(1):34–42. doi:https://doi.org/10.1016/j.jclinepi.2006.03.012.
- Mandrekar JN. Receiver operating characteristic curve in diagnostic test assessment. J Thorac Oncol. 2010 Sept 1;5(9):1315–16. doi:https://doi.org/10.1097/JTO.0b013e3181ec173d.
- Ousmen A, Touraine C, Deliu N, Cottone F, Bonnetain F, Efficace F, Brédart A, Mollevi C, Anota A. Distribution- and anchor-based methods to determine the minimally important difference on patient-reported outcome questionnaires in oncology: a structured review. Health Qual Life Outcomes. 2018 Dec 11;16(1):228. doi:https://doi.org/10.1186/s12955-018-1055-z.
- Vuillerot C, Payan C, Iwaz J, Ecochard R, Bérard C. Responsiveness of the motor function measure in patients with spinal muscular atrophy. Arch Phys Med Rehabil. 2013;94(8):1555–61. doi:https://doi.org/10.1016/j.apmr.2013.01.014.
- Domingos J, Muntoni F. Outcome measures in Duchenne muscular dystrophy: sensitivity to change, clinical meaningfulness, and implications for clinical trials. Dev Med Child Neurol. 2018;60(2):117. doi:https://doi.org/10.1111/dmcn.13634.
- Mouelhi Y, Jouve E, Castelli C, Gentile S. How is the minimal clinically important difference established in health-related quality of life instruments? Review of anchors and methods. Health Qual Life Outcomes. 2020 May 12;18(1):136. doi:https://doi.org/10.1186/s12955-020-01344-w.
- Terwee CB, Roorda LD, Dekker J, Bierma-Zeinstra SM, Peat G, Jordan KP, Croft P, de Vet HCW. Mind the MIC: large variation among populations and methods. J Clin Epidemiol. 2010;63(5):524–34. doi:https://doi.org/10.1016/j.jclinepi.2009.08.010.
- Revicki D, Hays RD, Cella D, Sloan J . Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol. 2008;61(2):102–09.
- McGlothlin AE, Lewis RJ. Minimal clinically important difference: defining what really matters to patients. JAMA. 2014;312(13):1342–43. doi:https://doi.org/10.1001/jama.2014.13128.
- King MT. A point of minimal important difference (MID): a critique of terminology and methods. Expert Rev Pharmacoecon Outcomes Res. 2011;11:171–84.
- Rai SK, Yazdany J, Fortin PR, Aviña-Zubieta JA . Approaches for estimating minimal clinically important differences in systemic lupus erythematosus. Arthritis Res Ther. 2015;17(1):1–8.
- Le Goff L, Meilleur KG, Norato G, Rippert P, Jain M, Fink M, Foley AR, Waite M, Donkervoort S, Bönnemann CG, Vuillerot C . Responsiveness and minimal clinically important difference of the motor function measure in collagen VI-related dystrophies and laminin Alpha2-related muscular dystrophy. Arch Phys Med Rehabil. 2021;102(4):604–10.
- Wang Y-C, Hart DL, Stratford PW, Mioduski JE. Baseline dependency of minimal clinically important improvement. Phys Ther. 2011;91(5):675–88. doi:https://doi.org/10.2522/ptj.20100229.
- Enright PL. The six-minute walk test. Respir Care. 2003;48:783–85.
- Mazzone E, Messina S, Vasco G, Main M, Eagle M, D’Amico A, Doglio L, Politano L, Cavallaro F, Frosini S, et al. Reliability of the North Star Ambulatory Assessment in a multicentric setting. Neuromuscul Disord. 2009;19(7):458–61. doi:https://doi.org/10.1016/j.nmd.2009.06.368.
- Steffensen BF, Hyde SA, Attermann J, Mattsson E. Reliability of the EK scale, a functional test for non-ambulatory persons with Duchenne dystrophy. Adv Physiother. 2002;4(1):37–47. doi:https://doi.org/10.1080/140381902317303195.
- Main M, Kairon H, Mercuri E, Muntoni F. The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation. Eur J Paediatr Neurol. 2003;7(4):155–59. doi:https://doi.org/10.1016/S1090-3798(03)00060-6.
- Bartels B, Pangalila RF, Bergen MP, Cobben NA, Stam HJ, Roebroeck ME . Upper limb function in adults with Duchenne muscular dystrophy. J Rehabil Med. 2011;43(9):770–75. doi:https://doi.org/10.2340/16501977-0841.